ANTITUMOR ACTIVITY OF A NOVEL FGFR INHIBITOR IN INTRAHEPATIC CHOLANGIOCARCINOMA

被引：0

作者：

Raggi, Chiara ^{[1
]}

Fiaccadori, Karim ^{[2
]}

Pastore, Mirella ^{[1
]}

Correnti, Margherita ^{[2
]}

Piombanti, Benedetta ^{[1
]}

Forti, Elisa ^{[2
]}

Navari, Nadia ^{[1
]}

Abbadessa, Giovanni ^{[3
]}

Hall, Terence ^{[3
]}

Destro, Annarita ^{[2
]}

Di Tommaso, Luca ^{[4
]}

Roncalli, Massimo ^{[5
]}

Meng, Fanyin ^{[6
,7
]}

Glaser, Shannon S. ^{[8
]}

Rovida, Elisabetta ^{[1
]}

Peraldo-Neia, Caterina ^{[9
]}

Olaizola, Paula ^{[10
]}

Banales, Jesus M. ^{[10
]}

Gerussi, Alessio ^{[11
,12
]}

Elvevi, Alessandra ^{[11
,12
]}

Busset, Michele Droz Dit ^{[13
]}

Bhoori, Sherrie ^{[14
]}

Mazzaferro, Vincenzo ^{[15
]}

Alpini, Gianfranco ^{[16
,17
,18
]}

Marra, Fabio ^{[19
]}

Invernizzi, Pietro ^{[20
]}

机构：

[1] Univ Florence, Florence, Italy

[2] Humanitas Clin & Res Ctr, Rozzano, Italy

[3] Arqule Inc, Woburn, MA USA

[4] Humanitas Res Inst, Rozzano, MI, Italy

[5] Humanitas Res Hosp, Pathol Unit, Rozzano, MI, Italy

[6] Richard L Roudebush VA Med Ctr, Div Gastroenterol & Hepatol, Dept Med, Indianapolis, IN USA

[7] Indiana Univ, Bloomington, IN 47405 USA

[8] Texas A&m Hlth Sci Ctr, Bryan, TX USA

[9] Fdn Edo & Elvo Tempia, Canc Genom Lab 8, Biella, Italy

[10] Univ Basque Country UPV EHU, Dept Liver & Gastrointestinal Dis, Biodonostia Res Inst, Donostia Univ Hosp,Ciberehd,Ikerbasque, Leioa, Spain

[11] Univ Milano Bicocca, Div Gastroenterol, San Gerardo Hosp, Dept Med & Surg, Monza, Italy

[12] Univ Milano Bicocca, Ctr Autoimmune Liver Dis, San Gerardo Hosp, Dept Med & Surg, Monza, Italy

[13] Ist Nazl Tumori Irccs Fdn, Hpb Surg & Liver Transplantat, Milan, Italy

[14] Ist Nazl Tumori Irccs Fdn, Gastroenterol & Liver Transplant Hepatol, Milan, Italy

[15] Natl Tumor Inst, Milan, Italy

[16] Richard L Roudebush VA Med Ctr, Indianapolis, IN USA

[17] Indiana Univ, Gastroenterol, Med, Bloomington, IN 47405 USA

[18] Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN USA

[19] Univ Florence, Dipartimento Med Sperimentale & Clin, Florence, Italy

[20] Univ Milano Bicocca, Dept Med & Surg, Monza, Italy

来源：

HEPATOLOGY | 2019年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

355

引用

页码：226A / 227A

页数：2

共 50 条

[21] TARGETING FGFR2-FUSIONS WITH ANTIBODY THERAPEUTICS IN INTRAHEPATIC CHOLANGIOCARCINOMA
Chaturantabut, Saireudee
Oliver, Sydney
Federick, Dennie T.
Kim, John
Robinson, Foxy
Sellers, William R.
HEPATOLOGY, 2023, 78 : S2139 - S2139
[22] Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma
Gile, Jennifer J.
Wookey, Vanessa
Zemla, Tyler J.
Shi, Qian
Jin, Zhaohui
Alberts, Steven R.
McWilliams, Robert R.
Ma, Wen Wee
Borad, Mitesh
Bekaii-Saab, Tanios S.
Tran, Nguyen H.
Mahipal, Amit
TARGETED ONCOLOGY, 2022, 17 (05) : 529 - 538
[23] Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma
Jennifer J. Gile
Vanessa Wookey
Tyler J. Zemla
Qian Shi
Zhaohui Jin
Steven R. Alberts
Robert R. McWilliams
Wen Wee Ma
Mitesh Borad
Tanios S. Bekaii-Saab
Nguyen H. Tran
Amit Mahipal
Targeted Oncology, 2022, 17 : 529 - 538
[24] Preclinical antitumor activity of S 49076, a novel MET / AXL / FGFR kinase inhibitor and molecular stratification for tumor sensitivity
Burbridge, Mike F.
Bossard, Celine
Saunier, Carine
Fejes, Imre
Bruno, Alain
Pierre, Alain
Guigal-Stephan, Nolwen
Rodriguez, Marianne
Galizzi, Jean-Pierre
Lockhart, Brian P.
Jacquet-Bescond, Anne
Ortuno, Jean-Claude
Cruzalegui, Francisco H.
Depil, Stephane
CANCER RESEARCH, 2012, 72
[25] Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma
Lamarca, A.
Vogel, A.
ESMO OPEN, 2023, 8 (06)
[26] Development of a Novel Model for Intrahepatic Cholangiocarcinoma
Marcus, R. K.
Foo, W.
Evans, D.
Maitra, A.
Gupta, S.
ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : S104 - S104
[27] ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
Holmstrom, Tim H.
Moilanen, Anu-Maarit
Ikonen, Tarja
Bjorkman, Mari L.
Linnanen, Tero
Wohlfahrt, Gerd
Karlsson, Stefan
Oksala, Riikka
Korjamo, Timo
Samajdar, Susanta
Rajagopalan, Srinivasan
Chelur, Shekar
Narayanan, Kishore
Ramachandra, Raghuveer K.
Mani, Jiju
Nair, Rashmi
Gowda, Nagaraj
Anthony, Thomas
Dhodheri, Samiulla
Mukherjee, Subhendu
Ujjinamatada, Ravi K.
Srinivas, Nanduri
Ramachandra, Murali
Kallio, Pekka J.
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (01) : 28 - 38
[28] Characterization of two novel oncogenic FGFR2 fusions sensitive to the FGFR-selective inhibitor Debio 1347 in cholangiocarcinoma
Vaslin, Anne
Rigotti, Stefania
Lembrez, Nathalie
Vuagniaux, Gregoire
Moulon, Corinne
Tanaka, Hiroaki
CANCER RESEARCH, 2015, 75
[29] Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma
Chai, Xiaoqiang
Wang, Jie
Li, Huanping
Gao, Chao
Li, Shuangqi
Wei, Chuanyuan
Huang, Jianhang
Tian, Yingming
Yuan, Jian
Lu, Jiacheng
Gao, Dongmei
Zheng, Yimin
Huang, Cheng
Zhou, Jian
Shi, Guoming
Ke, Aiwu
Liu, Feng
Fan, Jia
Cai, Jiabin
GUT MICROBES, 2023, 15 (01)
[30] E7090, a novel and selective FGFR inhibitor, for the treatment of cholangiocarcinoma cells harboring FGFR2-fusion genes
Miyano, Saori W.
Arai, Yasuhito
Matsui, Junji
Shibata, Tatsuhiro
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →